Keyphrases
Adverse Events
100%
Systemic Lupus Erythematosus
100%
Infliximab
100%
TNF Blockade
100%
Lupus Nephritis
22%
Short-term Treatment
22%
Long-term Treatment
22%
Long-term Efficacy
22%
Interstitial Lung Disease
22%
Immunosuppression
11%
Life-threatening
11%
Extracting Information
11%
Deep Vein Thrombosis
11%
Safety Trial
11%
Long-term Response
11%
Primary Central Nervous System Lymphoma (PCNSL)
11%
Retreatment
11%
Severe Adverse Events
11%
Fatal Accidents
11%
Compassionate Care
11%
Drug Reaction
11%
Legionella Pneumonia
11%
Organ Inflammation
11%
Lupus Arthritis
11%
Refractory SLE
11%
SLE Flare
11%
Medicine and Dentistry
Tumor Necrosis Factor
100%
Adverse Event
100%
Systemic Lupus Erythematosus
100%
Infliximab
100%
Infusion
33%
Lupus Nephritis
22%
Short Course Therapy
22%
Interstitial Lung Disease
22%
Infection
11%
Lupus Erythematosus
11%
Arthritis
11%
Immunosuppressive Treatment
11%
Deep Vein Thrombosis
11%
Retreatment
11%
Drug Hypersensitivity
11%
Legionella
11%
Pharmacology, Toxicology and Pharmaceutical Science
Tumor Necrosis Factor
100%
Adverse Event
100%
Systemic Lupus Erythematosus
100%
Infliximab
100%
Lupus Erythematosus Nephritis
22%
Interstitial Lung Disease
22%
Infection
11%
Inflammation
11%
Arthritis
11%
Deep Vein Thrombosis
11%
Legionella
11%
Immunology and Microbiology
Systemic Lupus Erythematosus
100%
Tumor Necrosis Factor
100%
Infliximab
100%
Lupus Erythematosus
33%
Nephritis
22%
Immunosuppression
11%
Vein
11%
Arthritis
11%
Legionella
11%
Drug Hypersensitivity
11%